To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

NCT02974426 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

132

Enrollment

OTHER

Sponsor class

Stopped Enrollment was delayed and the number of eligible patients significantly declined with the use of neoadjuvant or adjuvant ICIs and TKIs therapies. Thus, this trial was closed due to insufficient accrual.

Conditions

Non-small Cell Lung Cancer Stage IIIA
Radiotherapy

Interventions

RADIATION: PORT-first
RADIATION: PORT-last
DRUG: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

Sponsor

Shanghai Chest Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]